James Allison

James Allison received the 2018 Nobel Prize in Physiology or Medicine for his discovery of CTLA-4 as a cancer immunotherapy target and for his pivotal role in translating anti-CTLA-4 antibody (ipilimumab) from preclinical discovery to the landmark phase III melanoma trial demonstrating improved overall survival. His work established the first immune checkpoint blockade approval in oncology and launched the modern immunotherapy era. He continues to lead translational research on combination immunotherapy strategies and mechanisms of durable anti-tumor responses. Allison is arguably the most transformative figure in the history of cancer immunotherapy.